Table 1.

Mutation frequencies, together with MSI status, according to trial-arm (Arm A - continuous oxaliplatin-based chemotherapy, Arm B—continuous chemotherapy plus cetuximab, Arm C—intermittent chemotherapy)

Arm AArm BArm CTotal
GeneMutationNo. of samples with mutations/No. successfully analyzedNo. of samples with mutations/No. successfully analyzedNo. of samples with mutations/No. successfully analyzedNo. of samples with mutations/No. successfully analyzed
KRASG12A23/635 (3.6%)11/659 (1.7%)19/655 (2.9%)53/1,949 (2.7%)
KRASG12D74/635 (11.7%)94/659 (14.3%)73/655 (11.1%)241/1,949 (12.4%)
KRASG12V59/635 (9.3%)82/659 (12.4%)67/655 (10.2%)208/1,949 (10.7%)
KRASG12C23/635 (3.6%)14/659 (2.1%)31/655 (4.7%)68/1,949 (3.5%)
KRASG12R6/635 (0.9%)5/659 (0.8%)3/655 (0.5%)14/1,949 (0.7%)
KRASG12S14/635 (2.2%)20/659 (3.0%)9/655 (1.4%)43/1,949 (2.2%)
KRASG13C3/635 (0.5%)2/657 (0.9%)3/652 (0.5%)8/1,944 (0.4%)
KRASG13S0/635 (0%)0/657 (0%)1/652 (0.2%)1/1,944 (0.1%)
KRASG13D56/635 (8.8%)54/659 (8.2%)41/650 (6.3%)151/1,944 (7.8%)
KRASG13V0/635 (0%)1/659 (0.2%)0/650 (0%)1/1,944 (0.1%)
KRASQ61H5/518 (1.0%)8/541 (1.5%)6/539 (1.1%)19/1,598 (1.2%)
KRASQ61L2/633 (0.3%)3/656 (0.5%)3/648 (0.5%)8/1,937 (0.4%)
KRASQ61R3/633 (0.5%)3/656 (0.5%)2/648 (0.3%)8/1,937 (0.4%)
KRAS total268/635 (42.2%)297/659 (45.1%)259/655 (39.5%)824/1,949 (42.3%)
BRAFV600E50/632 (7.9%)40/661 (6.1%)64/651 (9.8%)154/1,944 (7.9%)
BRAFD594G7/622 (1.1%)5/655 (0.8%)9/649 (1.4%)21/1,926 (1.1%)
BRAF total57/632 (9.0%)45/662 (6.8%)73/652 (11.2%)175/1,946 (9.0%)
NRASG12C0/621 (0%)11/653 (1.7%)6/634 (1.0%)17/1,908 (0.9%)
NRASQ61K10/612 (1.6%)12/634 (1.9%)6/624 (1.0%)28/1,870 (1.5%)
NRASQ61L2/633 (0.3%)5/652 (0.8%)2/646 (0.3%)9/1,931 (0.5%)
NRASQ61R6/633 (1.0%)3/652 (0.5%)5/646 (0.8%)14/1,931 (0.7%)
NRAS total18/631 (2.9%)32/659 (4.9%)19/649 (2.9%)69/1,939 (3.6%)
PIK3CAE542K20/614 (3.3%)22/638 (3.4%)19/640 (3.0%)61/1,892 (3.2%)
PIK3CAE545K27/614 (4.4%)29/637 (4.6%)31/636 (4.9%)87/1,887 (4.6%)
PIK3CAQ546K3/612 (0.5%)10/630 (1.6%)6/623 (1.0%)19/1,865 (1.0%)
PIK3CAH1047L10/616 (1.6%)13/633 (2.1%)13/639 (2.0%)36/1,888 (1.9%)
PIK3CAH1047R13/616 (2.1%)14/633 (2.2%)19/639 (3.0%)46/1,888 (2.4%)
PIK3CA total71/620 (11.5%)85/643 (13.2%)87/644 (13.5%)243/1,907 (12.7%)
MSI19/502 (3.8%)26/520 (5.0%)21/543 (3.9%)66/1,565 (4.2%)

NOTE: Total numbers per locus do not exactly match individual numbers because: (i) for KRAS, 4 samples contained 2 independent mutations and 5 other samples contained uncharacterized mutations, (ii) for NRAS, one sample contained an uncharacterized mutation, and (iii) for PIK3CA, 6 samples contained 2 independent PIK3CA mutations. In those samples where genotypes were missing for rare mutations (with cumulative frequencies <1%), but where all other mutations were successfully tested as wild-type, an overall call of wild-type was made at that locus.